In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual ...

In late 2023/early 2024, CRISPR achieved a breakthrough in medical science after securing approval for Casgevy (exa-cel) across several countries, including the United States and Europe. This marked ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

A young boy, among the first in the UK to receive a revolutionary £1.65 million gene-editing treatment, has returned to the hospital where he was cared for to express his gratitude to the nurse who ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The ...

BOSTON — Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood ...